A pacemaker that restores the heart’s natural synchrony with the lungs.
Cysoni™ is an implantable pacemaker in development for people with heart failure who have no device therapy today. It restores the synchronisation between heart and lungs that is lost in heart failure.
Most heart failure patients have no device option.
Around 60 million people live with heart failure worldwide. Despite modern drug therapy, roughly half die within five years of diagnosis, and repeated hospital admissions make it one of the most expensive conditions health systems manage.
Cardiac resynchronisation therapy (CRT) is the only pacing therapy proven to help heart failure, but it is reserved for patients with a wide QRS complex. The majority of patients with reduced ejection fraction have a narrow QRS, so they are left on medication alone.
Cysoni is designed for exactly these patients: heart failure with reduced ejection fraction, in sinus rhythm, narrow QRS, not eligible for CRT, and still symptomatic on optimal medical therapy.
Sources: Global Burden of Disease; ESC Heart Failure Guidelines.
Heart–lung synchronisation, restored.
In a healthy person the heart and lungs work in synchrony. That synchronisation is lost in heart failure. Cysoni restores it.
Sense
The device monitors the patient’s breathing and heart rhythm continuously, in real time.
Compute
Patented bioelectronic circuits, modelled on the neurons that control breathing and heart rate, decide when each beat should fall.
Pace
A single atrial lead delivers the synchronised pacing, using the same implant procedure as a conventional pacemaker.
Peer-reviewed research published in Journal of Physiology, Basic Research in Cardiology and Nature Communications.
32 patients randomised across five hospitals in the UK, Australia and New Zealand, using Ceryx’s pacing algorithm with a temporary external pacing system. Enrolment is complete and the full analysis is under way.
Ceryx has built its first implantable device and is developing the Cysoni implantable pulse generator with ISO 13485 partners, alongside an FDA regulatory strategy.
Working with Ceryx
We are talking to investors about our next funding round and to cardiac rhythm management companies about development and commercial partnerships. If that is you, we would like to hear from you.